Bright Minds Biosciences (NASDAQ:DRUG) Cut to “Sell” at Wall Street Zen
Wall Street Zen cut shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) from a hold rating to a sell rating in a report released on Thursday. Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald raised shares of Bright Minds Biosciences to a “strong-buy” rating in a research report […]
Wall Street Zen cut shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) from a hold rating to a sell rating in a report released on Thursday. Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald raised shares of Bright Minds Biosciences to a “strong-buy” rating in a research report […]
